Months after sparring rivals Amgen $AMGN and partners Regeneron $REGN and Sanofi
April 29, 2019 06:33 AM EDT Pharma As Praluent Q1 sales miss Wall Street expectations, FDA expands drug's label to reflect CV risk reduction Natalie Grover Reporter Months after sparring rivals Amgen $AMGN and partners Regeneron $REGN and Sanofi Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
